Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Johnson & Johnson

www.jnj.com

Latest From Johnson & Johnson

NRT Delivery Innovation Proposal In US Doesn't Deliver Expanded Indications

GSK's proposed usage for mouth spray product – reducing withdrawal symptoms, including nicotine craving – differs little from he first NRT product approved in US in 1984. Additional suggested label instructions primarily focus on stating NRTs can be used to reduce smoking or gradually stop tobacco use as opposed to quitting within a specified amount of time.

OTC Drugs Regulation

GSK Proposes Adding OTC Oral Spray To US Smoking Cessation Sector

FDA schedules Nonprescription Drugs Advisory Committee meeting 18 September to consider GSK's NDA for an OTC nicotine oral spray that delivers 1mg per spray.
Europe International

Generational Split In British Attitudes To Digital Self-Care, PAGB Research Finds

A survey by the UK’s self-care industry association, PAGB, has found a marked difference in generational attitudes to digital health apps and devices in the UK, with two-thirds of 18 to 35 year olds in the country trusting such technology compared to only a quarter of 46 to 55 year olds.

Wellness Dietary Supplements

Janssen's Imbruvica Leads CLL Market Expansion In Europe

Imbruvica is keeping ahead of potential competitors in Europe by expanding its use in patients with chronic lymphocytic leukemia and Waldenström’s macroglobulinemia.

 

Market Intelligence Cancer
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register